News | 22 August 2011
Generic drugmakers have forged a tentative deal with the US government that could see user fees being used to help the FDA inspect overseas active pharmaceutical ingredient manufacturing plants. The proposal could see almost $300 million in additional ...
Click on the link to read the full article at InPharm
(This link will open in a new window)